Table 5.
Progression-free survival and time to next antilymphoma treatment in the rituximab versus “watch-and-wait” study
| PNRNT 3 years | Differences between arms | HR p value | PFS 3 years | Differences between arms | HR p value | |
|---|---|---|---|---|---|---|
| W&W |
48% |
Rx4 vs W&W |
0.37 p < 0.001 |
33% |
Rx4 vs W&W |
0.46 p < 0.001 |
| Rx4 |
80% |
Rx4 + RM vs W&W |
0.20 p < 0.001 |
60% |
Rx4 + RM vs W&W |
0.21 p < 0.001 |
| Rx4 + RM | 91% | Rx4 + RM vs Rx4 | 0.57 p = 0.10 | 81% | Rx4 + RM vs Rx4 | 0.43 p < 0.001 |
PNRNT: patients not receiving next therapy; PFS: progression free survival; HR: hazard ratio ; W&W: watch and wait; Rx4: four weekly doses of rituximab; Rx4 + RM: four weekly doses of rituximab plus rituximab maintenance.